Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. - Wikidata - awgldk - TriplyDB

Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

http://www.wikidata.org/entity/Q34757266

about

Harnessing the immune system to improve cancer therapy Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors New Strategies for the Treatment of Solid Tumors with CAR-T Cells Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells CAR T cells for solid tumors: armed and ready to go?Genetic engineering with T cell receptors Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook Adoptive cell therapy for sarcoma CAR-modified T-cell therapy for cancer: an updated review.Mesenchymal stem cells genetically modified by lentivirus-mediated interleukin-12 inhibit malignant ascites in mice.New insights into IL-12-mediated tumor suppression.The Ikaros transcription factor regulates responsiveness to IL-12 and expression of IL-2 receptor alpha in mature, activated CD8 T cells.Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells The immune microenvironment of myeloma TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity.Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model.Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application.Genetically modified T-cell therapy for osteosarcoma Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.Identification and characterization of polyclonal αβ-T cells with dendritic cell properties.Interleukin-12 Immunomodulation Delays the Onset of Lethal Peritoneal Disease of Ovarian Cancer.New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies The p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit: implications for improved IL-12 cytokine production.Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.Collapse of the tumor stroma is triggered by IL-12 induction of Fas.Immunotherapeutic strategies to target prognostic and predictive markers of cancer."Model t" cells: a time-tested vehicle for gene therapy A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.Design and development of therapies using chimeric antigen receptor-expressing T cells GUCY2C-targeted cancer immunotherapy: past, present and future.Raising the bar: the curative potential of human cancer immunotherapy.Immunotherapy for the management of advanced melanoma: the next steps.Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.

P2860

Q26738698-E8D59BFF-694F-43CB-BF94-0B0BDFE1A6DD Q26741260-BE172893-DAD9-42F3-BCC5-97CA0BB0413A Q26748500-BAE83FDE-5D08-44D4-8492-794BA9053B7A Q26766184-B90326A5-62CD-4AB6-93FA-C544B49B0D30 Q26825489-0CD5915E-9DF8-411A-9730-85638FE9284A Q26995677-17EED414-A5EC-4234-B089-F1C7F8875DAE Q27002646-28ED6E20-E55B-4916-AB7F-AC770D265925 Q27004178-69A73A1D-D7D1-40ED-985B-1ACC54AD69CC Q27009541-2D41090D-0079-4986-A29C-6F33A989E215 Q34044213-7A9CFD6B-403B-4FCD-9AED-C7F809932AC7 Q34119602-27E6A6A2-A3D0-47A9-B0B8-56603053C082 Q34436897-943B41A5-A8EF-41E5-BF5F-CB6E5B40926F Q34618230-C7E7448E-CBDC-448B-BCF4-B5D963CAA7B6 Q34749359-775E3F7B-CD49-4B96-A6DC-8574D507E78B Q34985536-58E6F11A-D0C9-451C-8084-3905D070897C Q35578622-5C6DA8E1-8FAF-4566-9664-73C84A933ED2 Q35591391-64CAF00C-6180-479A-9F59-F7AFC3933EB9 Q35603152-AA78BEF2-6EE9-487D-92A4-14C4B4FF240B Q35612358-D1DAFE52-0B79-4684-9336-BA94CDEFFA0A Q35613148-361144F4-9250-4B27-ADB2-43031E8E9898 Q35674805-C0EE20EE-8163-4574-A046-2933467F0DF4 Q35810197-141FE135-75BD-4B20-AA6E-632F40527F7F Q35982211-B46B8E13-058F-4088-A45F-66ECC4542905 Q36198232-58A98F67-D46D-46C3-89E8-6D65DD36CE35 Q36366557-3F91C406-5A1F-483B-8DEB-A36E4C95ED2A Q36483058-BE728AFC-4FE5-486D-AEAE-47928390A198 Q36489567-C53BA1C8-9D02-47AE-AF7D-256A81847B24 Q36558375-21FD4082-7DDB-4056-BA2E-AC49535853C8 Q36647429-744A3524-1693-4F0B-B310-5CB230FFD395 Q36721440-5C882382-3703-48F5-81E1-E984AB55B88D Q36801106-8D75FB2A-3FDC-4C92-A718-92491430D243 Q36984473-EF8AD21B-6E5B-46C8-915A-0956C8618973 Q37126006-E4A3F678-A555-4A2D-A709-E7EEC460E7A6 Q37201423-88A18CC5-E4B6-4205-8C0A-0097A95A9D43 Q37362636-82130308-D3ED-42B6-AA56-3D53CADF2247 Q37418289-FB6AB5C5-3208-49E2-900C-22801C234F5B Q37950928-38275F73-D184-4880-9E40-18AE7286F660 Q37998451-EC15B9F8-7C2D-4DA6-8290-4EB069C35F0E Q38091675-F3C464B1-A7F6-4886-B6E6-B704CF9EC276 Q38146713-2DFB3742-B43A-4200-9944-2E977D156AC3

P2860

Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

http://www.wikidata.org/entity/Q34757266

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Improving adoptive T cell ther ...... sion to the tumor environment.

@ast

Improving adoptive T cell ther ...... sion to the tumor environment.

@en

Improving adoptive T cell ther ...... sion to the tumor environment.

@nl

type

label

Improving adoptive T cell ther ...... sion to the tumor environment.

@ast

Improving adoptive T cell ther ...... sion to the tumor environment.

@en

Improving adoptive T cell ther ...... sion to the tumor environment.

@nl

prefLabel

Improving adoptive T cell ther ...... sion to the tumor environment.

@ast

Improving adoptive T cell ther ...... sion to the tumor environment.

@en

Improving adoptive T cell ther ...... sion to the tumor environment.

@nl

P1433

Q34757266-55D1F3CB-8B78-4436-A02F-021D209CDD11

P1476

Q34757266-D633DE8E-2A61-428C-A6D3-45B250C89F3C

P2093

Q34757266-3F3F6C48-BD71-4F85-B7D7-A79DD5ABC5AC

Q34757266-570D7678-8327-4FB9-BB71-016B2F596621

Q34757266-5A8D710C-8D97-49E2-9A78-2DCAC106ADBB

Q34757266-6E612D3E-9E23-4348-B7EA-286F2E5C53BC

Q34757266-7FE4D874-1C2F-4E5E-BF77-A9BC83AF1280

Q34757266-AED0B892-6EE8-4756-8DC8-B9E1B11390D4

Q34757266-B76300A8-56BA-4440-8647-12128061769F

Q34757266-EF2C182D-589A-498A-A4B1-9A9C85121863

P2860

Q34757266-0E33A7C7-4EA4-4A50-A7C1-F2C01BEB5CDD

Q34757266-20DB6670-7593-421F-9F99-181DA0D0833D

Q34757266-274BC1F8-073F-4C9B-AA33-13C0FE75F117

Q34757266-28A92346-8C16-4FCD-8AF8-1A774DA01230

Q34757266-30455EB9-35AD-4088-9B66-12BB17CE96EF

Q34757266-34D1C6BC-F525-45ED-8106-A620DC41AEF2

Q34757266-430357E9-3FB4-4170-8CBD-65498A8FB202

Q34757266-4B598CD5-DD3B-4185-A1BF-1542B794D435

Q34757266-4B9210E5-2518-4F13-9BEB-9E5581A00D54

Q34757266-4C1CEBE8-01B1-446C-859C-E5110979052F

P304

Q34757266-C5890B58-2E51-47C9-AB08-03B13C6B9517

P31

Q34757266-70CFEFF0-136A-4CFC-A491-64025384261B

P356

Q34757266-31D7889F-F941-4375-8A2E-72FBD0EA0F0C

P433

Q34757266-7EE55363-CC2E-4810-A7AB-2E6A9FB321E6

P478

Q34757266-81F9B2FE-6F4F-4694-8BD3-F896359ECCDE

P577

Q34757266-A8ACCD6B-9038-49F0-BF86-0B6CFC1E69FC

P5875

Q34757266-1933D73E-A475-403D-A7C8-757AA7984EF8

P698

Q34757266-7586C55C-362A-4D6B-9329-13BBA2D7778B

P932

Q34757266-E944906D-860C-4D7B-8FF9-3D6B61DD9933

P356

P1433

Molecular Therapy

P1476

Improving adoptive T cell ther ...... sion to the tumor environment.

@en

P2093

Ling Zhang

http://www.w3.org/2001/XMLSchema#string

Nicholas P Restifo

http://www.w3.org/2001/XMLSchema#string

Richard A Morgan

http://www.w3.org/2001/XMLSchema#string

Shicheng Yang

http://www.w3.org/2001/XMLSchema#string

Sid P Kerkar

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

Zhili Zheng

http://www.w3.org/2001/XMLSchema#string

Zhiya Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Cancer regression in patients after transfer of genetically engineered lymphocytes

T cell activation

Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens.

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

The toxicology of interleukin-12: a review.

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts

P304

751-759

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2010.313

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49802731

http://www.w3.org/2001/XMLSchema#string

P698

21285960

http://www.w3.org/2001/XMLSchema#string

P932

3070103

http://www.w3.org/2001/XMLSchema#string